A VP35 Mutant Ebola Virus Lacks Virulence but Can Elicit Protective Immunity to Wild-Type Virus Challenge

A VP35 Mutant Ebola Virus Lacks Virulence but Can Elicit Protective Immunity to Wild-Type Virus Challenge

Summary: Zaire ebolavirus (EBOV) VP35 protein is a suppressor of type I interferon (IFN) production, an inhibitor of dendritic cell maturation, and a putative virulence determinant. Here, a recombinant EBOV encoding a mutant VP35 virus (VP35m) is demonstrated to activate RIG-I-like receptor signalin...

Full description

Bibliographic Details
Main Authors:	Courtney Woolsey, Andrea R. Menicucci, Robert W. Cross, Priya Luthra, Krystle N. Agans, Viktoriya Borisevich, Joan B. Geisbert, Chad E. Mire, Karla A. Fenton, Allen Jankeel, Sneha Anand, Hideki Ebihara, Thomas W. Geisbert, Ilhem Messaoudi, Christopher F. Basler
Format:	Article
Language:	English
Published:	Elsevier 2019-09-01
Series:	Cell Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2211124719310952

Similar Items

Transcriptome Analysis of Circulating Immune Cell Subsets Highlight the Role of Monocytes in Zaire Ebola Virus Makona Pathogenesis
by: Andrea R. Menicucci, et al.
Published: (2017-10-01)

Natural history of nonhuman primates after conjunctival exposure to Ebola virus
by: Robert W. Cross, et al.
Published: (2023-03-01)

Current state of Ebola virus vaccines: A snapshot
by: Courtney Woolsey, et al.
Published: (2021-12-01)

<italic toggle="yes">Bundibugyo ebolavirus</italic> Survival Is Associated with Early Activation of Adaptive Immunity and Reduced Myeloid-Derived Suppressor Cell Signaling
by: Courtney Woolsey, et al.
Published: (2021-08-01)

Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus.
by: Chad E Mire, et al.
Published: (2013-01-01)

Crimean-Congo hemorrhagic fever virus strains Hoti and Afghanistan cause viremia and mild clinical disease in cynomolgus monkeys.
by: Robert W Cross, et al.
Published: (2020-08-01)

Use of Single-Injection Recombinant Vesicular Stomatitis Virus Vaccine to Protect Nonhuman Primates Against Lethal Nipah Virus Disease
by: Chad E. Mire, et al.
Published: (2019-06-01)

Recombinant vesicular stomatitis virus–vectored vaccine induces long-lasting immunity against Nipah virus disease
by: Courtney Woolsey, et al.
Published: (2023-02-01)

A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus
by: Thomas W. Geisbert, et al.
Published: (2021-02-01)

A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge.
by: Courtney Woolsey, et al.
Published: (2022-05-01)

Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates.
by: Chad E Mire, et al.
Published: (2014-01-01)

Deep Sequencing Identifies Noncanonical Editing of Ebola and Marburg Virus RNAs in Infected Cells
by: Reed S. Shabman, et al.
Published: (2014-12-01)

Ebola virus VP30 and nucleoprotein interactions modulate viral RNA synthesis
by: Wei Xu, et al.
Published: (2017-06-01)

Recombinant Protein Filovirus Vaccines Protect Cynomolgus Macaques From Ebola, Sudan, and Marburg Viruses
by: Axel T. Lehrer, et al.
Published: (2021-08-01)

Natural history of Sudan ebolavirus infection in rhesus and cynomolgus macaques
by: Courtney Woolsey, et al.
Published: (2022-12-01)

The Marburg Virus VP24 Protein Interacts with Keap1 to Activate the Cytoprotective Antioxidant Response Pathway
by: Megan R. Edwards, et al.
Published: (2014-03-01)

Vesicular Stomatitis Virus–Based Vaccines against Lassa and Ebola Viruses
by: Andrea Marzi, et al.
Published: (2015-02-01)

The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus
by: Luke D. Jasenosky, et al.
Published: (2019-09-01)

Vesicular Stomatitis Virus-Based Vaccine Protects Mice against Crimean-Congo Hemorrhagic Fever
by: Sergio E. Rodriguez, et al.
Published: (2019-05-01)

Combination therapy with remdesivir and monoclonal antibodies protects nonhuman primates against advanced Sudan virus disease
by: Robert W. Cross, et al.
Published: (2022-05-01)

Monoclonal antibody therapy demonstrates increased virulence of a lineage VII strain of Lassa virus in nonhuman primates
by: Courtney Woolsey, et al.
Published: (2024-12-01)

Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys.
by: Wendelien B Oswald, et al.
Published: (2007-01-01)

Evaluation in Nonhuman Primates of Vaccines against Ebola Virus
by: Thomas W. Geisbert, et al.
Published: (2002-05-01)

Enhanced light microscopy visualization of virus particles from Zika virus to filamentous ebolaviruses.
by: George G Daaboul, et al.
Published: (2017-01-01)

The Ebola virus VP35 protein binds viral immunostimulatory and host RNAs identified through deep sequencing.
by: Kari A Dilley, et al.
Published: (2017-01-01)

Single dose rVSVΔG-JUNVGP vaccine protects guinea pigs against lethal Junin virus challenge
by: Teresa E. Sorvillo, et al.
Published: (2021-08-01)

Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment
by: Robert W. Cross, et al.
Published: (2020-07-01)

Ebola virus VP24 interacts with NP to facilitate nucleocapsid assembly and genome packaging
by: Logan Banadyga, et al.
Published: (2017-08-01)

Marburg and Ebola Virus Infections Elicit a Complex, Muted Inflammatory State in Bats
by: Anitha D. Jayaprakash, et al.
Published: (2023-01-01)

Safety of Recombinant VSV–Ebola Virus Vaccine Vector in Pigs
by: Emmie de Wit, et al.
Published: (2015-04-01)

A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.
by: David Safronetz, et al.
Published: (2015-04-01)

Domain rearrangement and denaturation in Ebola virus protein VP40
by: Rudramani Pokhrel, et al.
Published: (2018-12-01)

Effect of Ebola virus proteins GP, NP and VP35 on VP40 VLP morphology
by: Harty Ronald N, et al.
Published: (2006-05-01)

The Ebola Virus Interferon Antagonist VP24 Undergoes Active Nucleocytoplasmic Trafficking
by: Angela R. Harrison, et al.
Published: (2021-08-01)

An Intrinsically Disordered Peptide from Ebola Virus VP35 Controls Viral RNA Synthesis by Modulating Nucleoprotein-RNA Interactions
by: Daisy W. Leung, et al.
Published: (2015-04-01)

Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates.
by: Thomas W Geisbert, et al.
Published: (2008-11-01)

Cloning and expression of ebola virus GP and VP40 structural proteins
by: Lee, Carmen Ching Pei
Published: (2016)

The Ebola virus VP35 protein is a suppressor of RNA silencing.
by: Joost Haasnoot, et al.
Published: (2007-06-01)

Transcriptional Analysis of Infection With Early or Late Isolates From the 2013–2016 West Africa Ebola Virus Epidemic Does Not Suggest Attenuated Pathogenicity as a Result of Genetic Variation
by: Kevin J. Maroney, et al.
Published: (2021-08-01)

Identification of continuous human B-cell epitopes in the VP35, VP40, nucleoprotein and glycoprotein of Ebola virus.
by: Pierre Becquart, et al.
Published: (2014-01-01)